Cequent Pharmaceuticals Overview
- Founded
- 2003
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Latest Deal Amount
- $46M
Cequent Pharmaceuticals General Information
Description
Developer of RNAi based therapies. The company focuses on biopharmaceutical products based on RNA interference (RNAi) to prevent and treat a range of human diseases, such as inflammatory diseases and cancer.
Contact Information
Formerly Known As
Cequent
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Acquirer
Primary Office
- One Kendall Square
- Building 700, 1st Floor
- Cambridge, MA 02139
- United States
Cequent Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 01-Apr-2010 | $46M | 000.00 | 0000 | Completed | Product Development |
| 2. Later Stage VC (Series A1) | 30-Oct-2009 | 00.000 | 000.00 | 000.00 | Completed | Product Development |
| 1. Early Stage VC (Series A) | 15-Aug-2008 | $14.8M | $14.8M | 000.00 | Completed | Product Development |
Cequent Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.00 | 0.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Cequent Pharmaceuticals Patents
Cequent Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2009313930-A1 | E. coli mediated gene silencing of beta-catenin | Abandoned | 14-Nov-2008 | 00000000000 | |
| EP-2356235-A1 | E. coli mediated gene silencing of beta-catenin | Withdrawn | 14-Nov-2008 | 00000000000 | |
| CA-2742763-A1 | E. coli mediated gene silencing of beta-catenin | Abandoned | 14-Nov-2008 | 00000000000 | |
| US-20100189691-A1 | E. coli mediated gene silencing of beta-catenin | Abandoned | 14-Nov-2008 | 00000000000 | 0 |
| JP-2012508582-A | E. coli mediated gene silencing of β-catenin | Withdrawn | 14-Nov-2008 | C12N15/1135 |
Cequent Pharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ampersand Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| NMT Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| New England Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Pappas Capital | Venture Capital | Minority | 000 0000 | 000000 0 |